See feature article below: Capricor Therapeutics, Inc. (NASDAQ: CAPR)
Broad Street Alerts recent profiles and track record, 642% in verifiable potential gains for our members on 3 recent small cap alerts alone!
May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit over $4.15/share within 8 days for potential gains of 548% for our members.
May 23rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.
May 26th, 2016 (NASDAQ: CETX) opened at $2.00/share and hit $3.50/share within 10 days for potential gains of 74% for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report For: Capricor Therapeutics, Inc. (NASDAQ: CAPR)
Shares of CAPR are up 16% at $4.82 today on positive results of a 12 month long program to treat advanced heart disease in a DYNAMIC (see below) clinical trial. CAPR shares normally trade 16,000 shares per day and have exceeded that number today by a factor of 48.
Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Capricor’s lead candidate, CAP-1002 (allogeneic cardiosphere-derived cells), is in clinical development for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy as well as adult cardiology indications. Capricor is also advancing its research of its exosomes technology for various therapeutic areas. Its Cenderitide product candidate, a dual natriuretic peptide receptor agonist, has shown promise for the outpatient management of heart failure.
LOS ANGELES, June 16, 2016 /PRNewswire/ — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced positive preliminary 12-month data from its DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial, which evaluated CAP-1002 in patients with advanced heart failure. CAP-1002 is Capricor’s investigational allogeneic cardiosphere-derived cell (CDC) therapy.
In DYNAMIC, 14 patients with New York Heart Association (NYHA) Class III heart failure were treated with multi-vessel intracoronary infusion of CAP-1002 in four escalating dose cohorts. All patients received a one-time, triple-vessel infusion of CAP-1002 at doses ranging from 37.5 million to 75 million cells. Patients were followed for 12 months, and all echocardiographic studies were read by a core lab.
As observed at six months, directional improvements from baseline in key efficacy measures, including assessments of functional status, cardiac function and dimensions, and quality-of-life, were previously reported. Among these, statistically-significant (p
For the 12 patients available for follow-up at one year, improvements from baseline in key cardiac function and dimensional indices were directionally maintained. Importantly, the change in median left ventricular ejection fraction from baseline to 12 months maintained its level of statistical-significance at six months (p=0.02 at both timepoints) and, on an absolute basis, continued to improve from six to 12 months.
Of the five NYHA Class III subjects who received the highest dose of CAP-1002, two subjects improved by two Classes (to Class I) and three improved by one Class (to Class II) at six months. At 12 months, three of these five subjects were assessed as Class I and two as Class II, demonstrating further improvement and indicating durability of the benefit of CAP-1002 on heart failure status for as long as 12 months following administration. This 75 million cell dose is currently being evaluated in Capricor’s HOPE-Duchenne clinical trial in boys with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
CAP-1002 infusion was well-tolerated in DYNAMIC. Two of the 14 patients, who were in the lower two of the four dose cohorts, died from progressive heart failure approximately one and three months prior to study conclusion.
“I am very impressed with all aspects of these preliminary data, which show important and consistent improvements in cardiac structure and function. Class III patients are known to follow an inevitable course of clinical deterioration with progression of their heart failure. To see sustained improvements out to 12 months as shown in the DYNAMIC study is significant, and may herald a new treatment paradigm for the more than one million patients with advanced heart failure,” said Raj R. Makkar, M.D., Director, Interventional Cardiology and Cardiac Catheterization Laboratory, Cedars-Sinai Medical Center, and principal investigator of the trial.
Dr. Linda Marbán, president and chief executive officer of Capricor, commented, “We are very encouraged by the initial results demonstrated by CAP-1002 in this Class III population of advanced heart failure patients. Ejection fraction was improved and ventricular volumes were reduced, implying that CAP-1002 effected reverse remodeling. Importantly, the benefits of CAP-1002 were durable to 12 months. These data support the potential of Capricor’s CDCs to alter the prognosis of patients with chronic, advanced heart failure for whom current therapeutic options are limited.”
Dr. Marbán added, “Furthermore, the safety record of the triple-coronary infusion procedure used in DYNAMIC is supportive of the design of our randomized, 24-patient HOPE-Duchenne clinical trial, for which we expect top line data in the first quarter of 2017.”
In addition to the HOPE-Duchenne trial, Capricor is also evaluating CAP-1002 in the ALLSTAR clinical trial in adults with cardiac dysfunction following a myocardial infarction (heart attack).
About the DYNAMIC clinical trial
The Phase I DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial evaluated CAP-1002 (allogeneic cardiosphere-derived cells) in patients with advanced heart failure. The trial was open to patients with New York Heart Association (NYHA) Class III or ambulatory Class IV heart failure characterized by ischemic or non-ischemic dilated cardiomyopathy in which left ventricular ejection fraction was 35% or less. Suitable patients underwent sequential intracoronary infusion of CAP-1002 in up to three coronary territories. This triple vessel infusion was designed to broadly deliver cells to the myocardium, since patients with advanced heart failure have diffuse fibrosis throughout the heart.
Source – Company Press Release
DISCLAIMER
Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
Please Note: We do NOT accept free trading or restricted securities as payment for our services.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.
Stock market
Hot small cap stocks
small cap stock picks
Biotech stocks
FDA approval stocks
FDA calendar
Trade stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news
